What is it famous for? Its unique, non-hierarchical structure, which resulted from the vision of founding director Niels Jerne. He made the revolutionary decisions that the new institute should be devoted entirely to immunology, and that each researcher should be free to choose with whom and on what they work. The Basel Institute for Immunology, or BII, has no positions other than 'member' among the 50 scientific staff.
How is it funded?
The BII was set up 25 years ago by the pharmaceutical company Roche, which still fully funds it to the tune of about $25 million annually. This frees members from the tyranny of grant applications -they receive lab space, a technician and an annual supply budget of about $25 000.
What does Roche get out of it? Good, if expensive, public relations. Roche has an option on patenting work emerging from the BII, but rarely takes it up; it does not determine the direction of research.
Has it had any big successes? Niels Jerne's Nobel prize, awarded in 1984 for his influential ideas on specificity and control in the immune system, was shared with Georges Köhler, another BII member, and César Milstein, who jointly discovered the principle behind producing monoclonal antibodies. Perhaps the most famous son is Susumu Tonegawa, who received the Nobel prize in 1987 for his work at the BII on the generation of antibody diversity.
What is it like to work there? Most members find the BII (if not Basel itself) a stimulating, creative environment, though some visitors find the atmosphere of 'joyful disrespect' that Jerne fostered overly aggressive. There is a deliberate policy of rapid turnover, which prevents complacency; 80 % of members are on short-term contracts, lasting, on average, for four years. Not surprisingly, as labs are small, collaboration is the name of the game; about half of all projects are collaborations with other institutes.
Is it still non-hierarchical? In principle, yes, though some purists complain that the few permanent members hold increasing sway over the research direction of other members, so that the principle of individual freedom is threatened. The biggest challenge for current director Fritz Melchers (who succeeded Jerne in 1980) is to ensure that members are allowed to do their own thing, despite the pressures of established interests within, and competition from outside, the BII. 
What do they do for fun? Not easy in

